Almond Consumption Improves Inflammatory Profiles Independent of Weight Change: A 6-Week Randomized Controlled Trial in Adults with Obesity

Ayodeji Adepoju[1], Elaheh Rabbani[2], Philip Brickey[2], Victoria Vieira-Potter[2], Jaapna Dhillon[1,2]*

[1] Department of Nutrition and Exercise Physiology. School of Medicine. University of Missouri-Columbia
[2] Division of Food, Nutrition, and Exercise Sciences. College of Agriculture, Food and Natural Resources. University of Missouri-Columbia

*Correspondence: Jaapna Dhillon jdhillon@missouri.edu

Abstract

Background: Obesity is characterized by chronic low-grade systemic inflammation which can contribute to metabolic dysfunction. Diet is a modifiable factor that can help reduce this inflammation. Nuts such as almonds are rich in unsaturated fats, and antioxidant and anti-inflammatory micronutrients, which may work synergistically to attenuate obesity-related inflammation.

Objective: To investigate whether daily almond consumption improves systemic inflammatory and immune markers in adults with obesity.

Methods: In this randomized controlled parallel-arm trial, 69 adults (age: 30-45 years) with obesity (BMI: 30-45 kg/m^2) were assigned to consume either 58 g/day of almonds (n = 30) or an isocaloric ultra-processed snack (cookie; n = 30) for six weeks. Fasting serum pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ), anti-inflammatory IL-10, innate immune cell counts, body weight, glucose, insulin, and lipid profile were measured at baseline and week six. Dietary intake, food compliance, palatability, acceptance, and appetite ratings were also assessed.

Statistical analyses for primary outcomes included mixed model analyses and baseline-adjusted linear models.

Results: Food compliance was high for both groups with greater acceptance for almonds. Almond consumption significantly decreased serum IL-6, TNF-α, and IFN-γ and increased IL-10 over 6 weeks compared with the cookie group ($P < 0.05$). No significant group differences were observed for innate immune cell counts, body weight, blood pressure, or serum fasting glucose, insulin, total cholesterol (C), LDL-C, and triglycerides over six weeks. Almond intake also increased monounsaturated fat, fiber, alpha-tocopherol, magnesium, zinc, manganese, and improved HEI, MED, and DASH dietary pattern scores ($P<0.05$).

Conclusion: Daily almond consumption for six weeks improved inflammatory cytokine profiles and diet quality in adults with obesity, without changes in body weight under free-living conditions. These findings support almonds as part of healthy dietary patterns to help attenuate obesity-related inflammation.

Abbreviations:

DASH: Dietary approaches to stop hypertension
HEI: Healthy eating index
IFN: Interferon gamma
IL: Interleukin
MED: Mediterranean
TNF: Tumor necrosis factor

Clinical Trial Registry number: ClinicalTrials.gov ID: NCT05530499

Keywords: immune health; inflammation; dietary patterns; diet quality; nuts; appetite; metabolism; cardiovascular; ultra processed foods

Support: JD received research support from the Almond Board of California.

Introduction

Obesity is a state of chronic low-grade systemic inflammation, characterized by elevated circulating concentrations of pro-inflammatory cytokines and measurable shifts in innate immune cell populations (1,2). Adipose tissue expansion in obesity amplifies inflammatory signaling contributing to immune cell activation which eventually exacerbates systemic inflammation (1–3). This persistent inflammatory response is a key biological mechanism linking obesity to increased risk of insulin resistance, type 2 diabetes, and cardiovascular complications (4–7).

Diet is a modifiable factor that can help reduce the chronic low-grade systemic inflammation observed in obesity. Among various healthy eating patterns, the Mediterranean (MED)-style dietary pattern has consistently demonstrated beneficial effects on inflammatory and immune markers. Large epidemiological studies, including the Nurses' Health Study and the ATTICA study, report that higher adherence to a MED-style dietary pattern is associated with lower concentrations of pro-inflammatory cytokines and immune cell counts (8,9). For example, findings from the ATTICA study showed that participants with the highest adherence had on average, 17% lower IL-6 concentrations and 14% lower white blood cell counts compared to those with the lowest adherence. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) further support that MED-style dietary interventions reduce circulating inflammatory markers such as IL-6, IL-1β, and C-reactive protein (CRP) across diverse populations (10,11). Another systematic review on plant-based diets shows a reduction of IL-6 but not TNF-alpha for individuals with overweight and obesity with diverse health status such as metabolic syndrome CVD, or diabetes (12).

Nuts are a core component of high-quality dietary patterns (13) and may contribute substantially to the anti-inflammatory effects associated with these dietary patterns. Almonds, in particular, are among the most widely consumed tree nuts globally (14) and provide a variety of nutrients and bioactive compounds, including monounsaturated fats, vitamin E, zinc, magnesium, polyphenols, that are important for regulating inflammation, immune function, and oxidative stress (15–17). To date, most evidence on almonds and inflammation has been derived from studies in populations with diverse BMI and health status (18–20), leaving important gaps in the understanding of their effects specifically in obesity. Addressing these gaps could strengthen dietary recommendations aimed at lowering obesity-related inflammation and its metabolic consequences. Therefore, the primary objective of this randomized, controlled, parallel-arm clinical trial was to investigate the effects of six weeks of almond consumption on systemic immune and inflammatory markers in adults with obesity.

Methods

The procedures involving human participants in this study was approved by the Institutional Review Board of the University of Missouri-Columbia (Protocol number: 2090290). The study is registered on ClinicalTrials.gov (NCT05530499).

Participant Characteristics

Participants were recruited via public advertisements. Inclusion criteria included the following: (a) age 30–45 years old, (b) BMI of 30 – 45 kg/m², (c) willingness to maintain consistent diet and activity patterns, (d) willingness to consume almonds or cookies, (e) non-smokers over the past year, (e) and weight stable (no greater than 5 kg change over the last 3 months). Exclusion

criteria included diagnosed diabetes (fasting blood glucose >125 mg/dL), pregnant or lactating individuals, regular consumer of nuts (>3 times/week), planning on getting viral vaccines during study, allergies to study foods, illicit drug use, current use of medication that interfere with immune measures, recent start of medications that affect metabolism or appetite and drug therapy for coronary artery disease, peripheral artery disease, congestive heart failure or dyslipidemia. A total of 90 individuals were screened to determine eligibility for participation in this study and 69 participants started the study. The participant flow is depicted in **Figure 1**.

Study Design

The study was a 6-week randomized, controlled, parallel-arm intervention. Participants were assigned into one of two study arms: whole natural dry-roasted almonds (n = 38) or isocaloric control of cookies (n=31) via simple randomization. Participants in the almond group consumed 57 g/day (2 oz; 325 kcal) of dry-roasted almonds while those in the cookie group consumed 6 cookies/day (66g; 325 kcal). Compliance with study food consumption was monitored via daily text messages where participants reported their daily intake and time of consumption (morning, afternoon, evening). All outcomes were assessed before and after the 6-week intervention at minimum.

Sample Size Calculation

Sample size calculations for this study were informed by preliminary data from a previous intervention (21) involving a subset (n=20) of participants per group (almond vs. cracker) in young adults with mixed BMI status. In that population, we observed Cohen's d effect sizes ranging from small to moderate (d=0.19-0.60) for 8-wk changes in key markers such as IL-6, IL-

10, and TNF-alpha. Given that the current study targets a population of middle-aged adults with obesity, who typically exhibit greater baseline inflammation (22–26), we anticipated at least equal or larger effect sizes than those observed in the earlier cohort. Assuming a moderate effect size (Cohen's d = 0.6), a two-tailed alpha of 0.05, and 80% power, a sample size of approximately 25-30 participants per group was estimated to be sufficient to detect differences over 6 weeks in most markers.

Anthropometric and Cardiovascular Measurements

Height was measured to the nearest 1 mm using a stadiometer (SECA 216 Height Measuring Rod, SECA). Body weight was assessed in lightweight clothes to the nearest 100 g using standard calibrated electronic scales. Waist and hip circumferences were recorded at the narrowest part of the torso and the widest part of the hips-gluteal region respectively using a standard measuring tape. Resting systolic and diastolic blood pressure (BP) was assessed using an OMRON automatic BP device (model BP:725, Kyoto, Japan) on the non-dominant arm after participants after five minutes of sitting. Height, weight, waist and hip circumferences, and blood pressure measurements were conducted twice and averaged for analysis. Body composition indices (fat-free mass (FFM), fat mass, and their percentages) were assessed using bioelectrical impedance analysis (BIA, RJL-Systems Quantum – V Segmental, Ref: Q5S) in a reclining position.

Blood Immune and Metabolic Marker Assessments

Blood samples were obtained using butterfly needle venipuncture after at least 8 hours of fasting.

Blood samples for white blood cells (WBC) assessments were collected in EDTA tubes while blood samples for tocopherol measurements were collected in light-protected tubes and transported to a Quest Diagnostics® laboratory for analysis. Differential WBC count i.e., absolute and proportions for lymphocytes, neutrophils, monocytes, eosinophils, and basophils were assessed using counting and microscopy methodologies. Tocopherol concentrations were assessed using chromatography methodology.

Serum samples were obtained from blood collected in serum separator tubes (SST) which were allowed to sit at for 1 hour before centrifugation for 10 min at 1.3 RCF. Serum samples were stored at −80 °C until analysis. Fasting serum glucose concentrations were measured using a YSI 2300 STAT Plus device (Yellow Springs, OH). Fasting serum triglycerides (TG; E-BC-K238), total cholesterol (TC; E-BC-K109-S), and high-density lipoprotein-cholesterol (HDL-C; E-BC-K221-M) concentrations were measured using commercially available kits (Elabscience®, USA). Low-density lipoprotein-cholesterol (LDL-C) was calculated using Friedwald equation LDL-C = [(TC – HDL-C) – (TG/2.2)] (27). The fasting serum concentrations of insulin (EZHI-14k), IL-6 (KAC1261), TNF-alpha (KAC1751), IFN-gamma (KAC1231), and IL-10 (KAC1321) were quantified using commercially available ELISA kits from Millipore (insulin) and Invitrogen for cytokines. Insulin sensitivity and resistance indices were calculated as we have done previously (28). Quantitative insulin-sensitivity check index (QUICKI), an estimate of fasting insulin sensitivity, was computed using [1/[log(fasting insulin μU/mL) + log(fasting glucose mg/dL)]. Homeostatic model assessment for insulin resistance (HOMA-IR), an estimate of fasting insulin resistance was computed using [fasting insulin (μU/L) × fasting glucose (mg/dL)/405].

Dietary Assessments

Dietary data were collected through a food frequency questionnaire recording intake over the past month using NCI's semi-quantitative Diet History Questionnaire III (DHQ III) (29). Total and detailed DHQ nutrient compositions were used to calculate Healthy Eating Index (HEI), Dietary Approaches to Stop Hypertension (DASH), and MED dietary pattern indices with the dietaryindex package in R (30). Self-administered 24-hour dietary recalls using ASA24® Dietary Assessment Tool (31) were also conducted.

Free-Living Appetite Ratings

The intensity of hunger, fullness, desire to eat, and prospective consumption were measured on electronic versions of 100-mm visual analog scales, with scale endpoints ranging from "not at all" to "extremely" (28). Participants recorded their responses every hour during the waking hours in a 24-h period. The time points between 8 am to 8 pm had the most complete data and were considered for further analysis. Morning, afternoon, evening, and total 12-hour period area under the curve (AUC) indices were computed using the trapezoidal rule.

Acceptance and Palatability Ratings

A 9-point food action rating scale assessed the weekly acceptability of almond and cookies (1 = "I would eat this if I were forced to" and 9 = "I would eat this every opportunity I had") (32). Additionally, the palatability of food items was evaluated weekly by a hedonic general labelled magnitude scale (gLMS) (100 = "Extremely unpalatable" and 100 = "Extremely palatable") (33).

Statistical Analyses

A linear mixed model analysis with nlme package (34) was conducted in R (version 4.1.0) for most outcomes with week (BL and W6) as the within-subject fixed effect, group (A and C) as the between-subject fixed effect, the week × group interaction, and participant as the random effect. For serum markers assessed via ELISA, the plate number was included as a random effect to control for variations according to plates. The group effect on total compliance % was analyzed by standard least squares regression. A GEE-based multinomial logistic regression was conducted in R using the multgee package (35) to evaluate whether the timing of consumption (morning, afternoon, evening) differed by group, accounting for repeated days of data per participant. FACT and palatability data were analyzed using nonparametric analysis of week (W1, W2, W3, W4, W5, and W6) and group interaction effects using the nparLD package in R (36).

For parametric analyses, data not meeting normality assumptions were transformed using the Johnson's family of transformations (37) in JMP Pro (version 17.0), however, only the non-transformed data are presented for interpretation purposes unless otherwise indicated. For parametric analyses, when statistically significant ($p<0.05$) effects were observed, contrasts were constructed and adjusted for multiple comparisons using the multivariate t distribution (mvt) adjustment in R (38). Baseline-adjusted analyses to determine adjusted group effects at week 6 were also conducted. For non-parametric analyses, post-hoc tests for significant effects were conducted using Mann Whitney analyses for between-subject factors, and nparLD for within-subject factors, with adjustments across contrasts using Benjamini-Hochberg correction.

Results

Participants Clinical and Biochemical Characteristics

There were no group differences in body weight, total fat mass %, total fat-free mass %, waist and hip circumferences, blood pressure, serum glucose, insulin, insulin sensitivity and resistance indices, tocopherol (alpha and beta-gamma) concentrations, and serum lipid profile (total cholesterol, LDL-C, and triglycerides) over the 6-week intervention (**Table 1**). HDL-C concentrations were higher in the almond group than in the cookie group at W6 (BL-adjusted group effect, $P<0.05$); however, this difference was largely driven by a tendency for HDL-C to decline in the cookie group (Group × Week Effect, $P \leq 0.05$; Mvt-adjusted within-group time effect, P-value ≤ 0.1).

Study Food Compliance and Acceptability

Mean subjective compliance percentage was high for both groups (Almond: 93.9% and Cookie: 92.5%) and no statistically significant group differences were observed. There were no group differences in time of consumption as well. Overall, almonds had higher acceptance than cookies (Group effect, $P<0.05$) but similar palatability, despite a decreasing trend in both acceptance and palatability for both groups over the 6-week intervention (Time Effect, $P<0.05$, **Table 2**).

Appetite Ratings

The 12-hour AUC for fullness was lower in the cookie group after 6 weeks of consumption while no changes were observed in 12-hour fullness AUC after 6 weeks of almond consumption (Group x Week Effect, $P<0.05$, **Table 3**). No group differences in morning, afternoon, evening, or 12-hour AUCs were observed for hunger, desire to eat, or prospective consumption ratings over the 6-week intervention.

Dietary Assessments

There were no significant group differences in DHQ-estimated or ASA-24 derived energy intake over the 6-week intervention (**Table 4** and **Supplementary Table 1**). All nutrients and indices were adjusted for energy intake in the subsequent analyses. The energy-adjusted analyses of the DHQ data shows that energy percentage from fat, total MUFA, oleic acid, total fiber, insoluble fiber, alpha-tocopherol, protein from nuts, calcium, magnesium, manganese, phosphorous, potassium, zinc, and dietary pattern scores for HEI, MED, and DASH were higher in the almond group, and energy percentage from carbohydrates, delta-tocopherol, and gamma-tocopherol, and refined grains intake were lower in the almond group compared to the cookie group at the end of the 6-week intervention (BL and Energy-adjusted Group Effect, $P<0.05$, Table 2). The findings from ASA24 dietary recall data were largely in agreement with the DHQ findings for the common variables, except for total energy % from fat, zinc, and refined grain intake, where no statistically significant or tendency for differences between groups at W6 were observed (Supplementary Table 1).

Immune and Inflammatory Marker Assessments

Overall, there were no group differences in immune markers over the 6-week intervention (**Figure 2**). However, almond consumption for 6 weeks resulted in lower concentrations of IL-6, TNF-alpha, IFN-gamma, and higher concentrations of IL-10 compared with cookie group (Week x Group Effect, $P<0.05$, BL-adjusted Group Effect, $P<.0.05$ **Figure 3, Supplemental Table 2**). Analyses for IL-10 were conducted on a subset of participants due to quality control issues affecting two assay plates, which rendered those data unusable.

Discussion

Almond consumption for six weeks lowered serum concentrations of pro-inflammatory cytokines, including IL-6, TNF-α, and IFN-γ, and increased the anti-inflammatory cytokine IL-10, compared to an isocaloric ultra-processed snack of cookies. These improvements in inflammatory markers occurred under weight-maintenance conditions and were accompanied by improvements in overall diet quality and higher acceptance of almonds relative to cookies. Interestingly, other than the tendency of a decline in HDL-C with cookie consumption, and decrease in 12-hour subjective fullness ratings, this ultra-processed food did not impact other physiological or inflammatory markers. Since no changes in other cardiometabolic markers were observed over the six-week period, the pattern supports the interpretation that changes in low-grade inflammation may occur earlier and potentially precede detectable changes in cardiometabolic markers, which may require longer durations to manifest (39,40).

The observed reductions in IL-6, TNF-α, and IFN-γ, alongside an increase in IL-10, suggest that daily almond intake may help shift the balance of systemic inflammatory signaling toward a less pro-inflammatory state in adults with obesity. Previous meta-analyses examining the effects of almond consumption on inflammatory markers have yielded mixed results. One meta-analysis found that almond intake significantly reduced circulating CRP concentrations in adults across varying BMI and health statuses, but did not report obesity-specific subgroup effects (18). Another found significant reductions in IL-6 overall, but these effects were more prominent in participants without obesity, however, with substantial heterogeneity observed within that subgroup (20). A third meta-analysis found that while CRP and IL-6 were significantly lowered overall, these changes were not significant for individuals with obesity, and no significant effect

overall was observed for TNF-α (19). While the present study did not assess CRP, the magnitude and consistency of changes across multiple cytokines (29–74% greater improvements in the almond group) suggest a stronger effect than previously reported in smaller or more heterogeneous populations. These effects were observed under free-living, weight-stable conditions, reinforcing that the nutrient composition of almonds, rather than energy restriction, mediated the cytokine shifts.

The observed shifts in cytokine profiles are biologically plausible given both the specific nutrient changes and the overall improvements in diet quality documented in this study. Participants who consumed almonds had higher intakes of total fat, specifically from monounsaturated fatty acids, primarily oleic acid, which are known to reduce pro-inflammatory lipid mediators when they displace dietary saturated fats (41–43). Additionally, almond consumption increased intake of alpha-tocopherol (vitamin E), a lipid-soluble antioxidant (44). Although no significant differences in serum alpha-tocopherol concentrations were observed between groups over the six-week period, this is consistent with previous findings suggesting that modest dietary increases may not rapidly alter circulating levels in individuals with normal baseline concentrations due to tight regulation and a saturable alpha-tocopherol pool (21).
Almond consumption also increased intakes of key minerals, including magnesium, zinc, and manganese which synergistically may help support healthy immune and antioxidant responses that counteract chronic low-grade inflammation (45–47). The almond group also had higher total fiber intake, driven mainly by the naturally high insoluble fiber content of almonds (approximately 80% of their total fiber (16)). Current evidence on how insoluble fiber influences inflammation, however, remains limited (48). Concurrently, participants in the cookie group had

higher intake of carbohydrates and refined grains. Collectively, these nutrient shifts were reflected in significantly higher HEI, MED, and DASH dietary pattern scores for the almond group compared to the cookie group. These dietary improvements with almond consumption likely acted through multiple complementary and synergistic pathways to produce the observed pattern of improved inflammation.

Notably, the almond intervention did not affect systemic innate or adaptive immune cell counts. This aligns with current understanding that obesity-related chronic inflammation is primarily driven by local immune cell infiltration and activation within adipose tissue which contributes to systemic inflammation (49–51), but does not necessarily cause large fluctuations in total circulating immune cell numbers over short periods. Although dietary patterns and weight loss can modulate this local immune environment and shift adipose tissue macrophage phenotypes (50), detecting corresponding changes in circulating blood counts may be challenging when there is no significant weight reduction, acute inflammatory challenge, or overt disease. While there are limited data on immune cells from nut-based studies, a systematic review found that vegetarian dietary patterns are associated with lower leukocyte counts in observational studies, yet intervention trials show inconsistent effects (52). In one eight-week DASH diet study, reduced lymphocyte counts were observed, but these occurred alongside weight and fat loss, suggesting that adiposity change may mediate the effect (53). Similarly, in a crossover trial, 4 week consumption of soy pudding modestly altered regulatory T cell counts, and in a 12-week RCT of a Brazilian cardioprotective diet with extra virgin olive oil, modest reductions in total leukocytes and lymphocyte-to-monocyte ratios were noted (54,55). Collectively, these studies highlight that weight loss and intervention duration strongly influence total leukocyte counts,

whereas shifts in immune cell subsets can occur with diet changes even without weight loss. Subtle immunological shifts may be better captured via adipose tissue analyses, gene expression profiling of isolated innate and adaptive cell subsets, and functional immune assays.

High compliance rates and higher acceptance scores for almonds compared to cookies underscore the feasibility of incorporating almonds into habitual eating patterns. Interestingly, cookies might have been expected to be more palatable due to their sweetness and ultra-processed characteristics, but there were no differences in palatability, and participants rated almonds as more acceptable overall. Appetite ratings showed that 12-hour subjective fullness declined over six weeks in the cookie group, which is consistent with research showing that low fiber and nutrient-poor snacks provide limited sustained satiety (56). In contrast, fullness remained stable in the almond group despite both snacks providing equivalent energy. Importantly, body weight remained stable in both groups, indicating effective energy compensation for both the ultra-processed cookie snack and almonds over 6 weeks. The findings are consistent with studies supporting that nuts do not contribute to positive energy balance when incorporated into a free-living diet (57–59).

The strengths of this study include its controlled design, high participant adherence, and stringent BMI and age criteria. However, the sample size, while adequate to detect changes in cytokine concentrations, may have limited power to detect more subtle changes in immune cell distributions. The relatively short duration precludes conclusions about long-term sustainability of these effects. Finally, participants were generally healthy aside from obesity, and effects in populations with more advanced metabolic disease may differ.

In conclusion, this study provides new evidence that daily almond consumption can improve inflammatory profiles in middle-aged adults with obesity, independent of weight change and under free-living conditions. These results, together with the observed improvements in diet quality support including almonds as a practical component of dietary strategies to help attenuate obesity-related inflammation. Longer-term studies with larger samples may be needed to determine whether the observed improvements in inflammation mediate improvements in cardiometabolic outcomes in obesity. Additionally, functional immunological analyses could provide further insight into the mechanisms underlying almond-induced improvements in inflammation.

Acknowledgements: JD and VVP designed research; JD, PB, and AA conducted research; JD, AA, ER analyzed data; and JD, AA, and ER wrote the first draft of the paper. All authors revised the paper. JD had primary responsibility for final content. All authors read and approved of the final manuscript.

Data Availability: Data described in the manuscript will be made available upon reasonable request pending completion of all study data analyses and publication.

Funding: Almond Board of California. The funding source had no role in the study design; collection, analysis, and interpretation of data; or writing and submission of the manuscript.

Author Disclosures: JD received funding from the Almond Board of California for this study. VVP is Co-Investigator on the grant. Other authors have no disclosures.

Declaration of Generative AI and AI-assisted technologies in the writing process: During the preparation of this work the authors used ChatGPT for editing and formatting purposes. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

References

1. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci AMS 2017;13:851–63.

2. Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: A Chronic Low-Grade Inflammation and Its Markers. Cureus [Internet] 2022 [cited 2025 May 30]; Available from: https://www.cureus.com/articles/86626-obesity-a-chronic-low-grade-inflammation-and-its-markers

3. Vieira-Potter VJ. Inflammation and macrophage modulation in adipose tissues. Cell Microbiol 2014;16:1484–92.

4. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity Elsevier BV; 2022;55:31–55.

5. Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Circ Res Ovid Technologies (Wolters Kluwer Health); 2020;126:1549–64.

6. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, Beguinot F. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol [Internet] Frontiers Media SA; 2020 [cited 2025 May 23];10. Available from: https://www.frontiersin.org/article/10.3389/fphys.2019.01607/full

7. Dali-Youcef N, Mecili M, Ricci R, Andrès E. Metabolic inflammation: Connecting obesity and insulin resistance. Ann Med Informa UK Limited; 2013;45:242–53.

8. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The Attica study. J Am Coll Cardiol 2004;44:152–8.

9. Fung TT, McCullough ML, Newby PK, Manson JE, Meigs JB, Rifai N, Willett WC, Hu FB. Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2005;82:163–73.

10. Koelman L, Egea Rodrigues C, Aleksandrova K. Effects of Dietary Patterns on Biomarkers of Inflammation and Immune Responses: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr Bethesda Md 2022;13:101–15.

11. Schwingshackl L, Hoffmann G. Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. Nutr Metab Cardiovasc Dis NMCD 2014;24:929–39.

12. Eichelmann F, Schwingshackl L, Fedirko V, Aleksandrova K. Effect of plant-based diets on obesity-related inflammatory profiles: a systematic review and meta-analysis of intervention trials. Obes Rev Off J Int Assoc Study Obes 2016;17:1067–79.

13. Glenn AJ, Aune D, Freisling H, Mohammadifard N, Kendall CWC, Salas-Salvadó J, Jenkins DJA, Hu FB, Sievenpiper JL. Nuts and Cardiovascular Disease Outcomes: A Review of the Evidence and Future Directions. Nutrients 2023;15:911.

14. Fortuny I. INC Statistical Yearbook Now Published – Key Insights Available to Members [Internet]. International Nut & Dried Fruit Council. 2024 [cited 2025 Aug 1]. Available from: https://inc.nutfruit.org/inc-statistical-yearbook-now-published-key-insights-available-to-members/

15. Singar S, Kadyan S, Patoine C, Park G, Arjmandi B, Nagpal R. The Effects of Almond Consumption on Cardiovascular Health and Gut Microbiome: A Comprehensive Review. Nutrients 2024;16:1964.

16. Barreca D, Nabavi SM, Sureda A, Rasekhian M, Raciti R, Silva AS, Annunziata G, Arnone A, Tenore GC, Süntar İ, et al. Almonds (Prunus Dulcis Mill. D. A. Webb): A Source of Nutrients and Health-Promoting Compounds. Nutrients Multidisciplinary Digital Publishing Institute; 2020;12:672.

17. Bolling BW, Chen C-YO, McKay DL, Blumberg JB. Tree nut phytochemicals: composition, antioxidant capacity, bioactivity, impact factors. A systematic review of almonds, Brazils, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts. Nutr Res Rev 2011;24:244–75.

18. Eslami M, Khaghani L, Moghadam EF. Effects of Almond Consumption on Selected Markers of Inflammation and Oxidative Stress: A Systematic Review and Meta-Analysis. Clin Nutr Res 2025;14:78–89.

19. Fatahi S, Daneshzad E, Lotfi K, Azadbakht L. The Effects of Almond Consumption on Inflammatory Biomarkers in Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Adv Nutr 2021;13:1462–75.

20. Hariri M, Amirkalali B, Baradaran HR, Gholami A. A systematic review and meta-analysis of almond effect on C-reactive protein and interleukin-6 in adults. Complement Ther Med 2023;72:102911.

21. Dhillon J, Newman JW, Fiehn O, Ortiz RM. Almond Consumption for 8 Weeks Altered Host and Microbial Metabolism in Comparison to a Control Snack in Young Adults. J Am Nutr Assoc Taylor & Francis; 2022;0:1–13.

22. Keramat SA, Alam K, Rana RH, Chowdhury R, Farjana F, Hashmi R, Gow J, Biddle SJH. Obesity and the risk of developing chronic diseases in middle-aged and older adults: Findings from an Australian longitudinal population survey, 2009–2017. PLOS ONE Public Library of Science; 2021;16:e0260158.

23. VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, Vos MB, Speliotes E, Terrault NA, Rinella ME, et al. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int 2018;38:706–14.

24. Norris T, Blodgett JM, Rogers NT, Hamer M, Pinto Pereira SM. Obesity in early adulthood and physical functioning in mid-life: Investigating the mediating role of c-reactive protein. Brain Behav Immun 2022;102:325–32.

25. Hafez W, Nasa P, Rashid A, Saleh H, Abuelsaoud HM, Abdelshakour M, Nashef Z, Abazid RR, Ahmed AB, Ahmed S, et al. Interleukin 6 (IL6) as a potential interplaying factor between obesity and COVID-19 outcome. Inform Med Unlocked 2024;45:101455.

26. Eswar S, Rajagopalan B, Ete K, Nageswara Rao Gattem S. Serum Tumor Necrosis Factor Alpha (TNF-α) Levels in Obese and Overweight Adults: Correlations With Metabolic Syndrome and Inflammatory Markers. Cureus 16:e64619.

27. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA 2013;310:2061.

28. Dhillon J, Thorwald M, De La Cruz N, Vu E, Asghar SA, Kuse Q, Diaz Rios LK, Ortiz RM. Glucoregulatory and Cardiometabolic Profiles of Almond vs. Cracker Snacking for 8 Weeks in Young Adults: A Randomized Controlled Trial. Nutrients 2018;10:960.

29. Diet History Questionnaire III (DHQ III) | EGRP/DCCPS/NCI/NIH [Internet]. [cited 2021 May 3]. Available from: https://epi.grants.cancer.gov/dhq3/

30. Zhan JJ, Hodge RA, Dunlop AL, Lee MM, Bui L, Liang D, Ferranti EP. Dietaryindex: A User-Friendly and Versatile R Package for Standardizing Dietary Pattern Analysis in Epidemiological and Clinical Studies [Internet]. 2023 [cited 2025 Mar 24]. Available from: http://biorxiv.org/lookup/doi/10.1101/2023.08.07.548466

31. Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool [Internet]. [cited 2017 Nov 22]. Available from: https://epi.grants.cancer.gov/asa24/

32. Schutz HG. Food Action Rating Scale for Measuring Food Acceptance. J Food Sci 1965;30:365–74.

33. Kalva JJ, Sims CA, Puentes LA, Snyder DJ, Bartoshuk LM. Comparison of the hedonic general Labeled Magnitude Scale with the hedonic 9-point scale. J Food Sci 2014;79:S238-245.

34. version) JP (S, to 2007) DB (up, to 2002) SD (up, to 2005) DS (up, authors (src/rs.f) E, sigma) SH (Author fixed, sigma) BVW (Programmer fixed, Ranke (varConstProp()) J, R Core Team. nlme: Linear and Nonlinear Mixed Effects Models [Internet]. 2022 [cited 2022 Nov 25]. Available from: https://CRAN.R-project.org/package=nlme

35. Touloumis A. R Package multgee: A Generalized Estimating Equations Solver for Multinomial Responses. J Stat Softw [Internet] 2015 [cited 2025 June 12];64. Available from: http://www.jstatsoft.org/v64/i08/

36. nparLD: An R Software Package for the Nonparametric Analysis of Longitudinal Data in Factorial Experiments | Noguchi | Journal of Statistical Software. [cited 2018 Sept 24]; Available from: https://www.jstatsoft.org/article/view/v050i12

37. Unistat Statistics Software | Quality Control-Data Transformation [Internet]. [cited 2022 Nov 2]. Available from: https://www.unistat.com/guide/quality-control-data-transformation/

38. Genz A, Bretz F, Miwa T, Mi X, Leisch F, Scheipl F, Bornkamp B, Maechler M, Hothorn T. mvtnorm: Multivariate Normal and t Distributions [Internet]. 2021 [cited 2022 Nov 2]. Available from: https://CRAN.R-project.org/package=mvtnorm

39. Pellegrini V, La Grotta R, Carreras F, Giuliani A, Sabbatinelli J, Olivieri F, Berra CC, Ceriello A, Prattichizzo F. Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment. Cells Multidisciplinary Digital Publishing Institute; 2024;13:1662.

40. Chiesa ST, Charakida M, Georgiopoulos G, Roberts JD, Stafford SJ, Park C, Mykkänen J, Kähönen M, Lehtimäki T, Ala□Korpela M, et al. Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2022;11:e024380.

41. Ravaut G, Légiot A, Bergeron K-F, Mounier C. Monounsaturated Fatty Acids in Obesity-Related Inflammation. Int J Mol Sci 2020;22:330.

42. Fritsche KL. The Science of Fatty Acids and Inflammation123. Adv Nutr 2015;6:293S-301S.

43. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001;276:16683–9.

44. Tucker JM, Townsend DM. Alpha-tocopherol: roles in prevention and therapy of human disease. Biomed Pharmacother Biomedecine Pharmacother 2005;59:380–7.

45. Rajaram S, Damasceno NRT, Braga RAM, Martinez R, Kris-Etherton P, Sala-Vila A. Effect of Nuts on Markers of Inflammation and Oxidative Stress: A Narrative Review. Nutrients 2023;15:1099.

46. Li L, Yang X. The Essential Element Manganese, Oxidative Stress, and Metabolic Diseases: Links and Interactions. Oxid Med Cell Longev 2018;2018:7580707.

47. Eslami M, Khaghani L, Moghadam EF. Effects of Almond Consumption on Selected Markers of Inflammation and Oxidative Stress: A Systematic Review and Meta-Analysis. Clin Nutr Res 2025;14:78–89.

48. Kabisch S, Hajir J, Sukhobaevskaia V, Weickert MO, Pfeiffer AFH. Impact of Dietary Fiber on Inflammation in Humans. Int J Mol Sci 2025;26:2000.

49. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796–808.

50. Thomas D, Apovian CM. Macrophage functions in lean and obese adipose tissue. Metabolism 2017;72:120–43.

51. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105:141–50.

52. Craddock JC, Neale EP, Peoples GE, Probst YC. Vegetarian-Based Dietary Patterns and their Relation with Inflammatory and Immune Biomarkers: A Systematic Review and Meta-Analysis. Adv Nutr 2019;10:433–51.

53. Rodríguez-López CP, González-Torres MC, Aguilar-Salinas CA, Nájera-Medina O. DASH Diet as a Proposal for Improvement in Cellular Immunity and Its Association with Metabolic Parameters in Persons with Overweight and Obesity. Nutrients 2021;13:3540.

54. Hasegawa Y, Noll AL, Lang DJ, Akfaly EM, Liu Z, Bolling BW. Low-fat yogurt consumption maintains biomarkers of immune function relative to nondairy control food in women with elevated BMI: A randomized controlled crossover trial. Nutr Res N Y N 2024;129:1–13.

55. Longhi R, Santos AS e A de C, López-Yerena A, Rodrigues APS, de Oliveira C, Silveira EA. The Effectiveness of Extra Virgin Olive Oil and the Traditional Brazilian Diet in Reducing the Inflammatory Profile of Individuals with Severe Obesity: A Randomized Clinical Trial. Nutrients 2021;13:4139.

56. Njike VY, Smith TM, Shuval O, Shuval K, Edshteyn I, Kalantari V, Yaroch AL. Snack Food, Satiety, and Weight123. Adv Nutr 2016;7:866–78.

57. Tan SY, Dhillon J, Mattes RD. A review of the effects of nuts on appetite, food intake, metabolism, and body weight123. Am J Clin Nutr 2014;100:412S-422S.

58. Guarneiri LL, Cooper JA. Intake of Nuts or Nut Products Does Not Lead to Weight Gain, Independent of Dietary Substitution Instructions: A Systematic Review and Meta-Analysis of Randomized Trials. Adv Nutr 2020;12:384–401.

59. Baer DJ, Dalton M, Blundell J, Finlayson G, Hu FB. Nuts, Energy Balance and Body Weight. Nutrients 2023;15:1162.

Figure Legend

Figure 1: Consort flow diagram of participants in the almond and cookie groups from enrollment to study completion.

Figure 2: Immune markers in the almond and cookie groups at baseline and week 6 in adults with obesity. **A:** Absolute basophil count. **B:** Basophils (%). **C:** Absolute eosinophil count. **D:** Eosinophils (%). **E:** Absolute monocyte count. **F:** Monocytes (%). **G:** Absolute neutrophil count. **H:** Neutrophils (%). **I:** Absolute lymphocyte count. **J:** Lymphocytes (%). **K:** White blood cell count.

Non-transformed data are presented as Mean ± SE.

Figure 3: Inflammatory markers in the almond and cookie groups at baseline and week 6 in adults with obesity. **A:** TNF-alpha. **B:** IFN-gamma. **C:** IL-6. **D:** IL-10.

Non-transformed data are presented as Mean ± SE. *BL-adjusted group effect P-value < 0.05. □ BL-adjusted group effect P-value <0.05 for JN transformed variable.

Table 1. Anthropometric, body composition, and clinical data for almond and cookie groups at baseline and week 6 in adults with obesity

	Baseline		Week 6		P-Values			
	Almond	**Cookie**	**Almond**	**Cookie**	**Group**	**Week**	**Group x Week**	**Baseline adjusted Group**
Weight (kg)	100.15 ± 14.91	99.96 ± 18.66	98.67 ± 14.6	98.82 ± 16.58	0.996	0.130	0.843	0.845
BMI (kg/m²)	36.15 ± 4.37	34.54 ± 3.18	35.74 ± 4.47	35.09 ± 3.49	0.252	0.509	0.414	0.257
Waist Circumference (cm)	102.31 ± 11.2	101.8 ± 9.93	101.87 ± 10.69	101.06 ± 9.74	0.785	0.301	0.788	0.714
Waist-Hip Ratio	0.85 ± 0.09	0.87 ± 0.08	0.85 ± 0.08	0.86 ± 0.08	0.276	0.106	0.829	0.793
BIA Fat%	44.02 ± 9.02	45.9 ± 4.32	46.91 ± 6.46	45.52 ± 5.64	0.846	0.151	0.062	0.135
BIA FFM%	55.98 ± 9.02	54.1 ± 4.32	53.09 ± 6.46	54.48 ± 5.64	0.846	0.151	0.062	0.135
Systolic BP (mmHg)	123.74 ± 11.55	123.63 ± 12.03	121.18 ± 9.26	121.68 ± 11.08	0.932	0.059	0.797	0.771
Diastolic BP (mmHg)	82.66 ± 7.02	80.77 ± 8.13	82.49 ± 6.71	80.17 ± 7.63	0.194	0.555	0.742	0.360
TG (mg/dL)	109.57 ± 62.67	82.78 ± 49.34	91.17 ± 41.91	90.48 ± 67.66	**0.039**	0.433	0.056	0.399
TC (mg/dL)	236.76 ± 42.84	221.43 ± 35.7	230.48 ± 50.77	232.33 ± 44.98	0.129	0.661	0.102	0.315
LDL (mg/dL)	159.92 ± 43.37	150.76 ± 31.18	157.25 ± 50.07	162.45 ± 38.25	0.319	0.361	0.145	0.283
HDL (mg/dL)	55.66 ± 7.22	52.36 ± 9.11^^	56.33 ± 8.37*	48.74 ± 6.69	0.073	0.170	**0.046**	**<0.001**
Glucose (mg/dL) □	105.68 ± 11.6	102.43 ± 9.63	106.86 ± 13.52	108.32 ± 12.47	0.345	0.079	0.408	0.703
Insulin (μU/mL) □	20.01 ± 13.69*	14.48 ± 9.56	16.87 ± 14.37	14.38 ± 8.5	**0.010**	0.200	**0.039**	0.936
HOMA-IR □	5.25 ± 3.83*	3.72 ± 2.57	4.4 ± 3.58	3.87 ± 2.37	**0.010**	0.380	**0.039**	0.836
QUICKI □	0.31 ± 0.03*	0.33 ± 0.03	0.32 ± 0.03	0.33 ± 0.05	**0.010**	0.373	**0.048**	0.934
α-tocopherol (mg/L)	12.13 ± 4.36	11 ± 2.71	11.62 ± 3.67	11.26 ± 2.98	0.278	0.769	0.386	0.957
β-γ tocopherol (mg/L)	1.48 ± 0.61	1.69 ± 0.7	1.77 ± 0.92	1.7 ± 0.66	0.512	0.052	0.063	0.299

Non-transformed data presented as Mean ± SD. □ Indicates P-values reported for JN transformed variable. *Mvt-adjusted pairwise P-value ≤ 0.05 for Almond vs. Cookie within the same timepoint. **Mvt-adjusted pairwise P-value ≤ 0.05 for BL vs. W6 within the same group. ^^ Mvt-adjusted pairwise P-value ≤ 0.1 for BL vs. W6 within the same group.

QUICKI, quantitative insulin-sensitivity check index; HOMA-IR, homeostatic model assessment for insulin resistance; FFMI, fat-free mass index; TC, total cholesterol; HDL, high density lipoproteins; LDL, low density lipoproteins; TG, triglycerides; BP, blood pressure; WHR, Waist to hip ratio

Table 2. Acceptance and palatability ratings of study foods at baseline and week 6 in adults with obesity

	Week	Almond Median (IQR)	Cookie Median (IQR)	P-Values
FACT Scale	**Week 1** ^, **	6 (6 - 7)	5 (5 - 6)	Group: **0.015** Time: **<0.001** Group x Time: 0.520
	Week 2 ^, **	6 (5 - 7)	5 (5 - 6)	
	Week 3 **	6 (5 - 7)	5 (5 - 6)	
	Week 4 *,**	6 (4.25 - 7)	6 (5 - 6)	
	Week 5 **	6 (3.25 - 7)	5 (4 - 6)	
	Week 6	5.5 (4.75 - 7)	5 (3.25 - 5.75)	
Palatability (/100mm)	**Week 1**	58.62 (41.93 - 64.53)	58.14 (41.18 - 73.27)	Group: 0.503 Time: **0.034** Group x Time: 0.398
	Week 2 ^, ^^	58.62 (50.3 - 63.75)	57.22 (41.38 - 70.78)	
	Week 3	57.28 (35.67 - 65.15)	56.82 (44.71 - 72.09)	
	Week 4 ^, ^^	58.28 (41.23 - 66.57)	58.62 (50.46 - 68.08)	
	Week 5	51.16 (41.28 - 64.12)	57.47 (44.22 - 60.35)	
	Week 6	54.95 (41.38 - 65.2)	56.62 (46.65 - 60)	

Data shown are Medians (IQR). Nonparametric analyses were conducted using nparld. ***BH-adjusted pairwise P-value ≤ 0.05 for timepoint vs. W5; ****BH-adjusted pairwise P-value ≤ 0.05 for timepoint vs. W6; ^BH-adjusted pairwise P-value ≤ 0.1 for timepoint vs. W5; ^^ BH-adjusted pairwise P-value ≤ 0.1 for timepoint vs. W6.

Table 3. Subjective appetite ratings for almond and cookie groups at baseline and week 6 in adults with obesity

	Baseline		Week 6		P-Values		
	Almond	**Cookie**	**Almond**	**Cookie**	**Group**	**Week**	**Group x Week**
Hunger							
Morning AUC	70.4 ± 32.09	62.45 ± 35.72	68.84 ± 33.99	82.04 ± 45.88	0.376	0.119	0.067
Afternoon AUC	85.11 ± 37.2	84.34 ± 48.55	75.27 ± 38.63	73.83 ± 39.25	0.939	0.105	0.957
Evening AUC	44.04 ± 25.51	33.5 ± 27.28	39.58 ± 19.3	38.77 ± 26.32	0.078	0.912	0.180
12-Hour AUC	199.55 ± 56.74	180.28 ± 80.14	183.69 ± 77.75	194.64 ± 88.87	0.298	0.943	0.153
Fullness							
Morning AUC	118.46 ± 47.21	130.28 ± 52.48	121.52 ± 39.78	108.06 ± 50.34	0.305	0.138	0.051
Afternoon AUC	159.39 ± 54.04	160.96 ± 67.36	167.65 ± 49.06	155.28 ± 73.19	0.916	0.839	0.272
Evening AUC	112.27 ± 33.69	116.7 ± 37.4	107.11 ± 31.25	98.81 ± 39.04	0.605	**0.005**	0.125
12-Hour AUC	390.12 ± 113.47	407.94 ± 138.92**	396.27 ± 101.23	362.14 ± 146.39	0.557	0.101	**0.032**
Desire to Eat							
Morning AUC	73.02 ± 28.58	69.06 ± 40.21	68.13 ± 35.76	78.35 ± 49.38	0.674	0.700	0.214
Afternoon AUC	81.64 ± 41.46	88.41 ± 50.11	66.89 ± 31.2	73.23 ± 43.94	0.506	**0.016**	0.973
Evening AUC	43.46 ± 27.91	39.82 ± 29.99	35.27 ± 19.09	40.31 ± 27.37	0.569	0.336	0.279
12-Hour AUC	198.12 ± 59.39	197.29 ± 86.99	170.29 ± 68.08	191.89 ± 95.87	0.965	0.096	0.261
Prospective Consumption							
Morning AUC	74.55 ± 29.78	72.09 ± 37.4	70.04 ± 29.85	81.88 ± 49.59	0.784	0.613	0.171
Afternoon AUC	84.77 ± 36.18	103.19 ± 53.7	76.87 ± 33.02	78.03 ± 41.84	0.067	**0.002**	0.106
Evening AUC	44.62 ± 24.77	41.54 ± 32.65	41.29 ± 21.1	42.41 ± 24.13	0.624	0.743	0.577
12-Hour AUC	203.94 ± 62.42	216.83 ± 92.81	188.21 ± 67.03	202.31 ± 99.74	0.512	0.103	0.948

Non-transformed data presented as Mean ± SD. Values are AUC x 10^2. **Mvt-adjusted pairwise P-value ≤ 0.05 for BL vs. W6 within the same group.

Table 4. Self-reported dietary intake (energy-adjusted) from the Diet History Questionnaire III for the almond and cookie groups at baseline and week 6 in adults with obesity.

	Baseline		**Week 6**		**P-Values**			
	Almond	**Cookie**	**Almond**	**Cookie**	**Group**	**Week**	**Group x Week**	**BL-adjusted Group**
Carbohydrate (g)	170.48 ± 5.01	169.75 ± 5.56	160.98 ± 5	173.35 ± 5.54	0.400	0.301	**0.022**	**0.016**
Carbohydrate (% energy)	46.39 ± 1.43**	46.81 ± 1.59	42.85 ± 1.43	46.7 ± 1.58	0.274	**0.036**	**0.049**	**0.027**
Total fat (g)	61.68 ± 1.79	58.98 ± 1.99	67.48 ± 1.79	61 ± 1.98	**0.048**	**0.003**	0.158	**0.014**
Fat (% energy)	36.81 ± 1.08	35.12 ± 1.2	40.95 ± 1.08	36.67 ± 1.2	**0.036**	**<0.001**	0.094	**0.016**
Total MUFA (g)	22.52 ± 0.79**	21.27 ± 0.88	27.5 ± 0.79*	22.14 ± 0.87	**0.001**	**<0.001**	**0.002**	**<0.001**
Octadecenoic acid (g)	20.83 ± 0.75**	19.54 ± 0.83	25.86 ± 0.75*	20.53 ± 0.82	**<0.001**	**<0.001**	**0.002**	**<0.001**
Total PUFA (g)	13.41 ± 0.41	12.5 ± 0.46	14.35 ± 0.41	12.87 ± 0.45	**0.017**	0.060	0.415	0.121
Total protein (g)	64.86 ± 2.62	69.22 ± 2.91	63.08 ± 2.61	60.56 ± 2.89	0.781	0.012	0.098	0.175
Protein (% energy)	17.43 ± 0.6	17.94 ± 0.66	17.25 ± 0.6	16.32 ± 0.66	0.780	0.056	0.127	0.123
Nuts and seeds protein foods (oz)	0.72 ± 0.14**	0.42 ± 0.16	2.09 ± 0.14*	0.3 ± 0.16	**<0.001**	**<0.001**	**<0.001**	**<0.001**
Total dietary fiber (g)	16.4 ± 0.68	15.32 ± 0.75	17.17 ± 0.68*	13.79 ± 0.75	**0.010**	0.479	**0.032**	**0.008**
Insoluble dietary fiber (g)	10.53 ± 0.46	9.67 ± 0.51	11.39 ± 0.46*	8.59 ± 0.5	**0.001**	0.792	**0.018**	**0.001**
Soluble dietary fiber (g)	5.85 ± 0.39	5.65 ± 0.43	5.76 ± 0.39	5.17 ± 0.43	0.460	0.160	0.356	0.293
Total alpha-tocopherol (mg)	9.78 ± 0.8**	9.36 ± 0.89	15.96 ± 0.8*	8.06 ± 0.88	**<0.001**	**0.001**	**<0.001**	**<0.001**
Beta-tocopherol (mg)	0.35 ± 0.02**	0.3 ± 0.02	0.44 ± 0.02*	0.29 ± 0.02	**<0.001**	0.054	**0.009**	**0.001**
Delta-tocopherol (mg)	1.97 ± 0.12	1.84 ± 0.13**	1.89 ± 0.12*	2.74 ± 0.13	**0.007**	**<0.001**	**<0.001**	**<0.001**
Gamma-tocopherol (mg)	10.59 ± 0.47	9.64 ± 0.53	9.22 ± 0.47	10.81 ± 0.52	0.565	0.821	**0.004**	**0.002**
Calcium (mg)	853.8 ± 46.56**	875.47 ± 51.69**	968.09 ± 46.49*	737.41 ± 51.43	0.087	0.720	**<0.001**	**<0.001**
Magnesium (mg)	271.77 ± 11.82**	278.38 ± 13.12**	334.52 ± 11.8*	240.68 ± 13.06	**0.003**	0.201	**<0.001**	**<0.001**
Manganese (mg)	2.78 ± 0.14**	2.65 ± 0.16	3.13 ± 0.14*	2.44 ± 0.16	**0.027**	0.482	**0.005**	**0.001**
Phosphorus (mg)	1071.1 ± 36.55	1148.57 ± 40.59**	1115.24 ± 36.5	986.19 ± 40.38	0.563	0.062	**0.001**	**<0.001**

Potassium (mg)	2207.92 ± 64.8	2204.87 ± 71.92**	2227.46 ± 64.71*	1974.35 ± 71.6	0.144	**0.010**	**0.002**	**<0.001**
Zinc (mg)	8.81 ± 0.32	9.01 ± 0.36**	9.25 ± 0.32*	8.02 ± 0.36	0.210	0.280	**0.006**	**0.003**
Refined grain (oz)	3.05 ± 0.17	2.79 ± 0.19**	2.75 ± 0.17*	4.12 ± 0.19	**0.006**	**0.001**	**<0.001**	**<0.001**
Nuts, seeds, soy, legumes (oz)	1.21 ± 0.16**	0.97 ± 0.17	2.67 ± 0.16*	0.66 ± 0.17	**<0.001**	**<0.001**	**<0.001**	**<0.001**
HEI-2015 index	63.76 ± 1.37	63.88 ± 1.52**	65.49 ± 1.37*	56.07 ± 1.51	**0.008**	**0.004**	**<0.001**	**<0.001**
Mediterranean index	4.34 ± 0.25	3.96 ± 0.27	4.7 ± 0.25*	3.48 ± 0.27	**0.010**	0.764	**0.031**	**0.004**
Nuts (Mediterranean index)	0.65 ± 0.07*	0.37 ± 0.08	0.78 ± 0.07*	0.24 ± 0.08	**<0.001**	0.977	**0.038**	**<0.001**
DASH index	24.13 ± 0.73	23.76 ± 0.81	25.38 ± 0.72*	22.18 ± 0.8	0.065	0.74	**0.004**	**<0.001**
Nuts, seeds, soy, and legumes (DASH)	1.2 ± 0.16**	0.96 ± 0.17	2.67 ± 0.16*	0.65 ± 0.17	**<0.001**	**<0.001**	**<0.001**	**<0.001**

Data are presented as model-adjusted least squares means ± SE. *Mvt-adjusted pairwise P-value ≤ 0.05 for Almond vs. Cookie within the same timepoint, **Mvt-adjusted pairwise P-value ≤ 0.05 for BL vs. W6 within the same group.


Enrollment
Assessed for eligibility (n = 90)
Excluded (n=7):
BMI criteria (n = 3)
Diabetes (n=3)
Frequent consumer of tree nuts (n=1)
Randomized (n=83)
Did not start study (n=14)
Allocation
Randomized to Almond group (n=38)
Randomized to Cookie group (n=31)
Follow-Up
Withdrew due to personal or medical reasons (n=3)
Disqualified due to pregnancy (n=1)
Withdrew due to personal or medical reasons (n=1)
Intent-to-Treat Analysis
Almond (n=38)
Cookie (n=31)


A
Almond
Cookie
Absolute Basophil Count (cells/µL)
B
Basophils (%)
C
Absolute Eosinophil Count (cells/µL)
D
Eosinophils (%)
E
Absolute Monocyte Count (cells/µL)
F
Monocytes (%)
G
Absolute Neutrophil Count (cells/µL)
H
Neutrophils (%)
I
Absolute Lymphocyte Count (cells/µL)
J
Lymphocytes (%)
K
White Blood Cell Count (10³ cells/µL)
BL
W6


A
Almond
Cookie
TNF-alpha (pg/mL)
0
10
20
30
40
50
60
BL
W6*
B
IFN-gamma (IU/mL)
0
1
2
3
4
5
6
BL
W6*
C
IL-6 (pg/mL)
0
10
20
30
40
50
60
70
BL
W6*
D
IL-10 (pg/mL)
0
10
20
30
40
50
BL
W6‡